Neurogene INC. (NGNE) — 8-K Filings

8-K Filings (26)

• Neurogene Inc. Files 8-K: Officer/Director Changes & Compensation — Apr 20, 2026 Risk: low
  Neurogene Inc. filed an 8-K on April 20, 2026, reporting changes in its officers and directors, along with compensatory arrangements. The filing also includes a
• Neurogene Files 8-K: Q4/FY25 Earnings & Corporate Presentation — Mar 24, 2026
  Neurogene Inc. filed an 8-K on March 24, 2026, to announce its results of operations and financial condition, specifically for the fourth quarter and year-end 2
• Neurogene Inc. Files 8-K on Nov 12, 2025 — Nov 12, 2025 Risk: medium
  Neurogene Inc. filed an 8-K on November 12, 2025, reporting on events that occurred on the same date. The filing is a current report under the Securities Exchan
• Neurogene Inc. Files 8-K: Regulation FD & Exhibits — Nov 6, 2025 Risk: low
  Neurogene Inc. filed an 8-K on November 6, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neo
• Neurogene Inc. Files 8-K with SEC — Oct 9, 2025 Risk: low
  Neurogene Inc. filed an 8-K on October 9, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Neoleukin Therap
• Neurogene Inc. Files 8-K with Regulatory Updates — Jun 30, 2025 Risk: low
  Neurogene Inc. filed an 8-K on June 30, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neol
• Neurogene Inc. Announces Director Changes and Officer Compensation — Jun 12, 2025 Risk: medium
  On June 12, 2025, Neurogene Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Jonathan Leff and the appoint
• Neurogene Inc. Files 8-K — Jun 9, 2025 Risk: low
  Neurogene Inc. filed an 8-K on June 9, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Neoleukin Therapeu
• Neurogene Inc. Files 8-K: Material Agreement, Other Events — Apr 14, 2025 Risk: medium
  On April 14, 2025, Neurogene Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/
• Neurogene Inc. Files 8-K with Financials and Reg FD Disclosure — Jan 13, 2025 Risk: low
  Neurogene Inc. filed an 8-K on January 13, 2025, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhi
• Neurogene Inc. Files 8-K: Regulation FD Disclosure — Nov 21, 2024 Risk: low
  Neurogene Inc. filed an 8-K on November 21, 2024, reporting an event on November 20, 2024. The filing is a Regulation FD Disclosure. The company, formerly known
• Neurogene Inc. Files 8-K: Regulation FD & Financials — Nov 12, 2024 Risk: low
  Neurogene Inc. filed an 8-K on November 11, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neo
• Neurogene Inc. Files 8-K: Material Agreement & Equity Sales — Nov 4, 2024 Risk: medium
  On November 4, 2024, Neurogene Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securitie
• Amicus Therapeutics to Acquire Neurogene for $3.9 Billion — Aug 7, 2024 Risk: medium
  Neurogene Inc. announced on August 7, 2024, that it has entered into a definitive agreement to be acquired by Amicus Therapeutics, Inc. for approximately $3.9 b
• Neurogene Inc. Files 8-K for Disclosure and Exhibits — Jun 21, 2024 Risk: low
  Neurogene Inc. filed an 8-K on June 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleuk
• Neurogene Inc. Files 8-K Report — Jun 18, 2024 Risk: low
  On June 18, 2024, Neurogene Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Neurogene In
• Neurogene Inc. Files 8-K on Security Holder Vote — Jun 17, 2024 Risk: low
  Neurogene Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders on June 14, 2024. The company, formerly known as Neol
• Neurogene Inc. Files 8-K for Disclosure and Exhibits — Jun 3, 2024 Risk: low
  Neurogene Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleuki
• Neurogene Inc. Files 8-K on Operations and Financials — May 10, 2024 Risk: low
  Neurogene Inc. filed an 8-K on May 10, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The c
• Neurogene Inc. Files 8-K with Regulatory Disclosures — May 7, 2024 Risk: low
  Neurogene Inc. filed an 8-K on May 7, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin
• Neurogene Appoints New CMO, Adds Directors — Apr 25, 2024 Risk: medium
  Neurogene Inc. announced on April 19, 2024, the appointment of Dr. Steven A. Rosenberg as Chief Medical Officer and the election of Dr. Rosenberg and Dr. David
• Neurogene Inc. Files 8-K for Disclosure and Exhibits — Apr 22, 2024 Risk: low
  Neurogene Inc. filed an 8-K on April 22, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neo
• Neurogene Inc. Appoints New Directors, Adjusts Executive Compensation — Apr 2, 2024 Risk: medium
  Neurogene Inc. announced on April 1, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Steven M. Altschuler and Dr. Steven A
• Neurogene Inc. Files 8-K on Financials — Mar 18, 2024 Risk: low
  Neurogene Inc. filed an 8-K on March 18, 2024, reporting on its results of operations and financial condition. The filing indicates the company's principal exec
• Neurogene Inc. Files 8-K for Disclosure and Exhibits — Mar 4, 2024 Risk: low
  Neurogene Inc. filed an 8-K on March 4, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleuk
• Neurogene Inc. Reports Executive Changes and Compensation Adjustments — Feb 21, 2024 Risk: medium
  Neurogene Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 15, 2024. The filing pertains to the departure or election of dir

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX